Penumbra, Inc. — FY 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. The filing also reports unaudited fourth-quarter results. Penumbra designs, manufactures and sells interventional medical devices for neurovascular and peripheral vascular procedures, mainly to hospitals through direct sales and selected distributors.
Financial performance and position
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $186.1 million | $125.5 million |
| Gross profit / margin | $124.1 million / 66.7% | $82.8 million / 66.0% |
| Operating income / margin | $4.2 million / 2.2% | $3.0 million / 2.4% |
| Net income | $2.4 million | $2.2 million |
| Net cash used in operations | $22.3 million | $6.4 million |
Revenue grew 48.3%. Neuro revenue was $141.4 million, up 33.1%; peripheral vascular revenue was $44.7 million, up 131.9%. International sales were 31.6% of revenue. Gross margin improved 0.7 percentage points; operating expenses rose 50.1% to $119.9 million, led by higher SG&A.
Fourth-quarter revenue was $54.4 million, gross profit $36.5 million, net income $1.6 million and diluted EPS $0.05. The company reported FY diluted EPS of $0.08. The audited statements report $1.084 million of FY net income attributable to common stockholders, while the selected financial data table reports $0.719 million; the filing text is inconsistent on this value.
At year-end, cash and cash equivalents were $19.5 million, marketable investments $129.3 million, working capital $216.2 million and total assets $263.8 million. Total liabilities were $31.3 million; the company reported no long-term debt. Operating cash use was driven principally by inventory growth of $25.1 million and higher receivables. The IPO generated $124.7 million in net proceeds; cash and investments together totaled $148.8 million.
Material changes versus prior year
- Revenue growth was supported by broader salesforce reach, product penetration and new or expanded offerings. Penumbra System products accounted for about half of the revenue increase; Indigo contributed more than half of peripheral vascular growth.
- SG&A increased 58.5% to $101.9 million, including $24.1 million more compensation expense, expanded marketing, public-company costs and salesforce travel. R&D increased 15.7% to $18.0 million.
- Cash used in operations increased from $6.4 million to $22.3 million, while inventory rose from $33.5 million to $56.8 million.
- Following its September 2015 IPO, convertible preferred stock converted to common stock; year-end stockholders’ equity was $232.5 million versus a $12.4 million deficit a year earlier.
Outlook, risks and unusual items
- Management said it expected liquidity to meet requirements for at least the next 12 months. No quantified revenue or earnings guidance is provided. Management expects stroke-market and peripheral vascular growth rates to moderate from recent rapid levels and anticipates continued investment in products, manufacturing, sales and international expansion.
- Key risks include dependence on neuro products and clinical adoption, competition, reimbursement and pricing pressure, regulatory clearance, single-site manufacturing, supplier concentration, inventory obsolescence, foreign exchange exposure and the costs of rapid growth. The company had no foreign-exchange hedges.
- FDA inspections in 2015 produced two Form 483 observations: clinical-trial monitoring at five sites and documentation of CAPA effectiveness checks. Penumbra reported corrective actions; the FDA said the monitoring response appeared adequate, while CAPA actions could be reviewed at a future inspection.
- An IDE study of the 3D stroke device was temporarily suspended by its Data Safety Monitoring Board after 198 of 230 planned patients enrolled. The filing states the suspension was not due to safety issues; the board was assessing data.
- A product-liability complaint filed in February 2016 concerns an aneurysm procedure using the Penumbra Coil 400. The claimant’s counsel had cited a possible $35 million jury award, substantially above insurance coverage. Penumbra said it could not assess the merits at that early stage and intended to defend the case.
- Year-end contractual obligations included $75.5 million of rent, $0.95 million of equipment leases and $11.8 million of purchase commitments. A new Alameda lease added 99,568 square feet and may expand further.
Important facts for investors to verify
- Reconcile the conflicting FY 2015 common-stockholder income figures ($1.084 million in the audited statements versus $0.719 million in selected data).
- Track operating cash use, inventory and receivables growth against sales growth and production capacity.
- Monitor whether recent stroke-market procedure growth and peripheral vascular adoption continue as management expects, and review product mix and margins.
- Follow the 3D study suspension, FDA follow-up on inspection observations, and the Coil 400 litigation, including potential exposure relative to insurance.
- Assess the cost and funding implications of the expanded facility commitments, ongoing salesforce growth and public-company expenses.